17P - Can subtyping diagnosis help in optimizing the management of lung adenocarcinoma patients?

Date 28 March 2014
Event ELCC 2014
Session Lunch and poster display session
Topics Lung and other Thoracic Tumours
Pathology/Molecular Biology
Presenter Tatiana Kondratieva
Citation Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131
Authors T.T. Kondratieva1, N. Velizheva2, M.V. Dardyk3, A. Pavlovskaya4, N. Mazurenko5, I. Tsyganova5, S. Subramanian6
  • 1Clinical Cytology Laboratory, Clinical Oncology Research Institute, FSBI N. N. Blokhin RCRC RAMS, 115478 - Moscow/RU
  • 2Laboratory Of Cell Imunity, Research Institute of Experimental Diagnostics and Tumor Therapy, FSBI N. N. Blokhin RCRC RAMS, 115478 - Moscow/RU
  • 3Department Of Oncology, Moscow State University of Medicine and Dentistry, 127473 - Moscow/RU
  • 4Human Tumor Pathologic Anatomy Department, Clinical Oncology Research Institute, FSBI N. N. Blokhin RCRC RAMS, 115478 - Moscow/RU
  • 5Laboratory Of Oncogenomics, Research Institute of Carcinogenesis, FSBI N. N. Blokhin RCRC RAMS, 115478 - Moscow/RU
  • 6-, Eurasian Federation of Oncology, 129226 - Moscow/RU

Abstract

In the era of targeted therapy of metastatic and locally advanced lung cancer (LC) the final verdict already often belongs to genetists. Is it reasonable to do molecular screening for 80% of LC that are NSCLC? Are the advantages worth the price of research? Are there any correlations between molecular changes, morphological features of different histological subtypes, clinical implications and prognosis of disease? 1. To evaluate the need and clinical significance of subtyping lung cancer adenocarcinomas (AC) on small biopsies and cytological samples in daily practice 2. To analyze the correlation between histologic subtypes of Lung AC, EGFR/KRAS-status and efficiency of the treatment in LC patients.